Literature DB >> 15679412

The genesis of Barrett esophagus: has a histologic transition from gastroesophageal reflux disease-damaged epithelium to columnar metaplasia ever been seen in humans?

Robert H Riddell1.   

Abstract

Has a histologic transition from gastroesophageal reflux disease-damaged epithelium to columnar metaplasia ever been seen in humans? The answer to this question seems to be that it has but that we either do not readily recognize it or it is not readily recognizable with regular light microscopy. There are at least 3 possible mechanisms for the genesis of Barrett esophagus. The first is ulceration at the gastroesophageal junction with subsequent repair by an epithelium that differentiates into Barrett epithelium. The second is metaplasia through multilayered epithelium. The third is creeping columnar metaplasia at the Z-line proximally followed by intestinalization. These 3 hypotheses may not be mutually exclusive, and all may be operative, depending on the local circumstances, amount of inflammation, erosion, ulcers, healing, acid and alkaline reflux, and use of proton pump inhibitors. Any of the epithelial types involved could be stable and not progress. They might even be reversible, which may also in part explain the mosaic of epithelial types that typify Barrett esophagus, and may be modified by any of the molecular mechanisms that turn protein transcription on and off (eg, promoter methylation, mutations). These mechanisms ultimately may also be involved in the genesis of neoplastic transformation.

Entities:  

Mesh:

Year:  2005        PMID: 15679412     DOI: 10.5858/2005-129-164-TGOBEH

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

1.  Histopathology of columnar-lined esophagus in patients with gastroesophageal reflux disease.

Authors:  Johannes Lenglinger; Claudia Ringhofer; Margit Eisler; Roland Sedivy; Fritz Wrba; Johannes Zacherl; Enrico P Cosentini; Gerhard Prager; Michael Haefner; Martin Riegler
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

2.  Videoendoscopy and histopathology of the esophagogastric junction in patients with gastroesophageal reflux disease.

Authors:  Claudia Ringhofer; Johannes Lenglinger; Margit Eisler; Fritz Wrba; Roland Sedivy; Johannes Zacherl; Enrico P Cosentini; Gerhard Prager; Elena Devyatko; Martin Riegler
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 3.  Barrett oesophagus: lessons on its origins from the lesion itself.

Authors:  Stuart A C McDonald; Danielle Lavery; Nicholas A Wright; Marnix Jansen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-04       Impact factor: 46.802

4.  Dietary Risk Reduction Factors for the Barrett's Esophagus-Esophageal Adenocarcinoma Continuum: A Review of the Recent Literature.

Authors:  Jessica L Petrick; Nan Li; Kathleen M McClain; Susan E Steck; Marilie D Gammon
Journal:  Curr Nutr Rep       Date:  2015-03-01

5.  Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease.

Authors:  Claudia Ringhofer; Johannes Lenglinger; Barbara Izay; Katharina Kolarik; Johannes Zacherl; Margit Eisler; Fritz Wrba; Parakrama T Chandrasoma; Enrico P Cosentini; Gerhard Prager; Martin Riegler
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

6.  Temporal trends of esophageal disorders by age in the Cerner Health Facts database.

Authors:  Jessica L Petrick; Tuyet Nguyen; Michael B Cook
Journal:  Ann Epidemiol       Date:  2015-12-11       Impact factor: 3.797

Review 7.  Current surgical treatment of esophagogastric junction adenocarcinoma.

Authors:  Shun Zhang; Hajime Orita; Tetsu Fukunaga
Journal:  World J Gastrointest Oncol       Date:  2019-08-15

8.  Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium.

Authors:  Jessica L Petrick; Nan Li; Lesley A Anderson; Leslie Bernstein; Douglas A Corley; Hashem B El Serag; Sheetal Hardikar; Linda M Liao; Geoffrey Liu; Liam J Murray; Joel H Rubenstein; Jennifer L Schneider; Nicholas J Shaheen; Aaron P Thrift; Piet A van den Brandt; Thomas L Vaughan; David C Whiteman; Anna H Wu; Wei K Zhao; Marilie D Gammon; Michael B Cook
Journal:  Cancer       Date:  2019-09-06       Impact factor: 6.921

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.